#pembrolizumab

[ follow ]
fromwww.theguardian.com
2 days ago

Treatment that can double bladder cancer survival rates available to 1,000 patients in England

Clinical trials of the drug have shown that people with bladder cancer that has spread (metastasised) live up to twice as long when given the combination antibody treatment when compared with those given normal chemotherapy. One trial also found that almost 30% of patients had no detectable traces of cancer in their body following treatment with enfortumab vedotin and pembrolizumab, compared with only 12.5% with chemotherapy.
Medicine
Cancer
fromwww.theguardian.com
2 months ago

Key takeaways from world's largest cancer conference in Chicago

Immunotherapy drugs like Keytruda and Car T-cell therapy show promise in significantly extending survival rates for cancer patients.
Cancer
fromwww.theguardian.com
2 months ago

Gift of life': experts hail neck and head cancer breakthrough

An immunotherapy drug can significantly prolong head and neck cancer remission, offering a major advancement in current treatment methods.
[ Load more ]